Dexlansoprazole

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 176 publications

Proton Pump Inhibitors and the Risk of Dementia.

Proton Pump Inhibitors and the Risk of Dementia.

Journal: The Journal of clinical psychiatry

Published: April 15, 2026

Intranasal Nanoemulsion-based In-Situ Gel Containing Dexlansoprazole: Formulation Development, In-Vitro and Ex-Vivo Evaluation.

Intranasal Nanoemulsion-based In-Situ Gel Containing Dexlansoprazole: Formulation Development, In-Vitro and Ex-Vivo Evaluation.

Journal: Drug development and industrial pharmacy

Published: April 11, 2026

A Vanished Association Between Proton Pump Inhibitors and Clostridioides Difficile Infection After Minimizing Bias.

A Vanished Association Between Proton Pump Inhibitors and Clostridioides Difficile Infection After Minimizing Bias.

Journal: Journal of clinical medicine

Published: November 09, 2025

Can Dual Delayed-Release Esomeprazole Replace Dexlansoprazole?

Can Dual Delayed-Release Esomeprazole Replace Dexlansoprazole?

Journal: Gut and liver

Published: July 15, 2025

Analysis of infection-related adverse events induced by proton pump inhibitors based on the FAERS and JADER databases.

Analysis of infection-related adverse events induced by proton pump inhibitors based on the FAERS and JADER databases.

Journal: Medicine

Published: April 15, 2025

So Many Choices, So Little Value: Potential Savings from Selecting Cost-Effective Proton Pump Inhibitors.

So Many Choices, So Little Value: Potential Savings from Selecting Cost-Effective Proton Pump Inhibitors.

Journal: PharmacoEconomics - open

Published: January 27, 2025

Quality by Design Formulation Approach for the Development of Orodispersible Tablets of Dexlansoprazole.

Quality by Design Formulation Approach for the Development of Orodispersible Tablets of Dexlansoprazole.

Journal: Drug design, development and therapy

Published: January 22, 2025

Comparative Efficacy of Dexlansoprazole, Pantoprazole, Esomeprazole, and Rabeprazole in Achieving Optimal 24-Hour Intragastric pH Control: A Randomized Crossover Study Using Ambulatory pH Monitoring.

Comparative Efficacy of Dexlansoprazole, Pantoprazole, Esomeprazole, and Rabeprazole in Achieving Optimal 24-Hour Intragastric pH Control: A Randomized Crossover Study Using Ambulatory pH Monitoring.

Journal: Cureus

Published: October 13, 2024

Dexlansoprazole is an aryl hydrocarbon receptor agonist.

Dexlansoprazole is an aryl hydrocarbon receptor agonist.

Journal: Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association

Published: October 01, 2024

Availability and Pricing of Drugs Prescribed by Otolaryngologists Through a Direct-to-Consumer Pharmacy: Medicare Savings Implications.

Availability and Pricing of Drugs Prescribed by Otolaryngologists Through a Direct-to-Consumer Pharmacy: Medicare Savings Implications.

Journal: Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery

Published: June 06, 2024

Delineating CYP2C19-mediated Interactions: Network Pharmacology Investigation of Ilaprazole and Clopidogrel versus Conventional Proton Pump Inhibitors.

Delineating CYP2C19-mediated Interactions: Network Pharmacology Investigation of Ilaprazole and Clopidogrel versus Conventional Proton Pump Inhibitors.

Journal: Current drug discovery technologies

Published: May 30, 2024

Identification of novel signal of proton pump inhibitor-associated drug reaction with eosinophilia and systemic symptoms: a disproportionality analysis.

Identification of novel signal of proton pump inhibitor-associated drug reaction with eosinophilia and systemic symptoms: a disproportionality analysis.

Journal: International journal of clinical pharmacy

Published: January 22, 2024

Showing 1-12 of 176

Last Updated: 04/28/2026